[1] Wang J, Cen P, Chen J, et al.Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure.Stem Cell Res Ther, 2017, 8(1):137.
[2] Huang S, Hu D, Yuan S, et al.The serum metabolomics study of liver failure and artificial liver therapy intervention. Med Sci Monit, 2021, 27:e930638.
[3] 倪清涛, 杨永峰.肝衰竭预后模型研究新进展.实用肝脏病杂志, 2016, 19(04):500-504.
[4] Mishra A, Rustgi V.Prognostic models in acute liver failure.Clin Liver Dis, 2018, 22(2):375-388.
[5] 楼夲.KCH标准、CTP评分、MELD评分以及MELD-Na评分在慢加急性肝衰竭中的应用.浙江大学, 2012.
[6] Acharya G, Kaushik RM, Gupta R, et al.Child-Turcotte-Pugh score, MELD score and MELD-Na score as predictors of short-term mortality among patients with end-stage liver disease in northern India.Inflamm Intest Dis, 2020, 5(1):1-10.
[7] Yarema MC, Johnson DW, Sivilotti M, et al.Predicting mortality from acetaminophen poisoning shortly after hospital presentation.Br J Clin Pharmacol, 2021, 87(8):3332-3343.
[8] Bernal W, Williams R.Beyond KCH selection and options in acute liver failure.Hepatol Int, 2018, 12(3):204-213.
[9] Du WB, Pan XP, Li LJ.Prognostic models for acute liver failure.Hepatobiliary Pancreat Dis Int, 2010, 9(2):122-128.
[10] Chen W, You J, Chen J, et al.Modified model for end-stage liver disease improves short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure.World J Gastroenterol, 2017, 23(40):7303-7309.
[11] Engelmann C, Thomsen KL, Zakeri N, et al.Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure.Crit Care, 2018, 22(1):254.
[12] Xun YH, Shi JP, Li CQ, et al.Prognostic performance of a series of model for end-stage liver disease and respective Δ scores in patients with hepatitis B acute-on-chronic liver failure.Mol Med Rep, 2014, 9(5):1559-1568.
[13] Brown C, Aksan N, Muir AJ.MELD-Na accurately predicts 6-month mortality in patients with decompensated cirrhosis: Potential trigger for hospice referral.J Clin Gastroenterol, 2021.
[14] 王雄伟, 郁毅刚, 姚猛飞, 等.创伤评分在危重症创伤患者评估中的应用.赣南医学院学报, 2022, 42(02):204-208+214.
[15] Kulkarni S, Sharma M, Rao PN, et al.Acute on chronic liver failure-in-hospital predictors of mortality in ICU.J Clin Exp Hepatol, 2018, 8(2):144-155.
[16] Duseja A, Choudhary NS, Gupta S, et al.APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF).J Dig Dis, 2013, 14(9):484-490.
[17] 马皖苏, 赵林, 李红生.CLIF-SOFA评分对HBV-ACLF患者器官衰竭的评估价值.肝脏, 2020, 25(06):578-581.
[18] Li J, Liang X, You S, et al.Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.J Hepatol, 2021, 75(5):1104-1115.
[19] Li N, Huang C, Yu KK, et al.Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure: The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF.Medicine (Baltimore), 2017, 96(17):e6802.
[20] Hernaez R, Solà E, Moreau R, et al.Acute-on-chronic liver failure: an update.Gut, 2017, 66(3):541-553.
[21] Choudhury A, Jindal A, Maiwall R, et al.Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models.Hepatol Int, 2017, 11(5):461-471.
[22] Sun J, Guo H, Yu X, et al.A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure.BMC Gastroenterol, 2021, 21(1):422.
[23] Wu T, Li J, Shao L, et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.Gut, 2018, 67(12):2181-2191.
[24] Wu D, Sun Z, Liu X, et al.HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure.Aliment Pharmacol Ther, 2018, 48(7):750-760.
[25] Zhang X, Han J, Qi X, et al.DIC score combined with CLIF-C OF score is more effective in predicting prognosis in patients with hepatitis b virus acute-on-chronic liver failure. Front Med (Lausanne), 2022, 9:815580.
[26] 邓春荣, 姜静, 任秀, 等.ABIC评分对HBV相关慢加急性肝衰竭患者短期生存情况的预测价值.胃肠病学, 2019, 24(07):411-415.
[27] 薛红, 明芳, 章颖, 等.ALBI评分对HBV相关慢加急性肝衰竭患者预后的预测价值. 交通医学, 2022, 36(01):33-36+40.
[28] Qiang L, Qin J, Sun C, et al.A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study.BMC Gastroenterol, 2020, 20(1):301.
[29] He Y, Hwang S, Ahmed YA, et al.Immunopathobiology and therapeutic targets related to cytokines in liver diseases.Cell Mol Immunol, 2021, 18(1):18-37.
[30] Kerbert A, Verspaget HW, Navarro àA, et al.Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival.Crit Care, 2017, 21(1):321.
[31] Hassan HM, Cai Q, Liang X, et al.Transcriptomics reveals immune-metabolism disorder in acute-on-chronic liver failure in rats. Life Sci Alliance, 2022, 5(3).
[32] Yan H, Jin S, Liang L, et al.Pro-adrenomedullin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival.Scand J Gastroenterol, 2020, 55(5):606-614.
[33] Engelmann C, Sheikh M, Sharma S, et al.Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.J Hepatol, 2020, 73(1):102-112.
[34] Sun S, Xu B, Tan W, et al.Testosterone and estradiol as novel prognostic indicators for HBV-related acute-on-chronic liver failure.Front Med (Lausanne), 2021, 8:729030. |
